Sort   by:  
 Page size 
TranscriptomicsThe HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR mutated and wildtype NSCLC cells
The receptor tyrosine kinase (RTK) EGFR is overexpressed and mutated in NSCLC. These mutations can be targeted by RTK inhibitors (TKIs), such as erlotinib. Chromatin-modifying agents offer a novel therapy approach by sensitizing tumor cells to TKIs. The NSCLC cell lines HCC827 (EGFR mutant, adenocar...
ORGANISM(S): Homo sapiens 
2014-12-03 | E-GEOD-63784 | biostudies-arrayexpress
Genomicsena-DATASET-DKFZ-IBIOS-29-08-2014-08:27:40:831-1015 - samples
Whole-exome sequencing of a chronic lymphocytic leukemia (CLL) developed during vemurafenib treatment of a patient with malignant melanoma. Peripheral blood mononuclear cells were separated by Ficoll gradient centrifugation. DNA was extracted from highly purified (>97%) CD19+CD5+ cells obtained from...
EGAD00001000997 | EGA
Genomicsena-DATASET-DKFZ-IBIOS-28-05-2015-11:13:32:451-82 - samples
Mutations that activate the RAF-MEK-ERK signaling pathway, in particular BRAFV600E, occur in many cancers, and mutant BRAF-selective inhibitors have clinical activity in these diseases. Activating BRAF alleles are usually considered to be mutually exclusive with mutant RAS, whereas inactivating muta...
EGAD00001001384 | EGA
GenomicsDKFZ-HIPO Project H021/NCT MASTER
Clinical genome and transcriptome sequencing in younger adults with advanced-stage cancer across all histologies: DKFZ-HIPO Project H021 (http://www.hipo-heidelberg.org/hipo2/index.php/menu-item-2/32-021-prospective-genetic-characterization-of-tumors-from-individual-patients-of-special-interest) / N...
EGAS00001000948 | EGA
Sort   by:  
 Page size